Clinical trials: Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, 5-fluorouracil and leucovorin compared systemic chemotherapy of gemcitabine and cisplatin in…
- Trial name
- NCT04961970
- Testing
- oxaliplatin , fluorouracil, and leucovorin, gemcitabine and cisplatin
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Shi Ming
Liver Cancer, Liver Metastases
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE.
- Trial name
- NCT07717437
- Where
- 31 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Maastricht University Medical Center
Intrahepatic Cholangiocarcinoma
Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is one of the most common liver malignancies. Surgical treatment is the first choice. However, for patients without surgical indications, the benefits of conventional chemoradiotherapy are…
- Trial name
- NCT03633773
- Testing
- MUC-1 CART cell immunotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Unresectable Intrahepatic Cholangiocarcinoma
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC.
- Trial name
- NCT02994251
- Testing
- gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Intrahepatic Cholangiocarcinoma
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.
- Trial name
- NCT04954781
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma (Icc)
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking.
- Trial name
- EXOMIC (NCT07224737)
- Testing
- EXOMIC small RNA sequencing, EXOMIC assay (qRT-PCR validation)
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- City of Hope Medical Center
ICC
Combining Chemoradiotherapy With Sintilimab in First-Line ICC
To evaluate the effectiveness and safety of GC (gemcitabine + cisplatin) and radiotherapy combined with slulimumab in the treatment of first-line intrahepatic cholangiocarcinoma patients
- Trial name
- NCT06447454
- Testing
- radiotherapy, gemcitabine + cisplatin, slulimumab
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Zhongshan Hospital
Intrahepatic Cholangiocarcinoma
Bortezomib in Intrahepatic Cholangiocellular Carcinoma
This study evaluates the efficacy and safety of second-line treatment of bortezomib in advanced intrahepatic cholangiocarcinoma patients.Half of participants will receive bortezomib while the other half will receive best…
- Trial name
- NCT03345303
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhengang Yuan
Adenocarcinoma Metastatic, Biliary Tract Cancer
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
AIO-YMO/HEP-0315 (NIFE) is an open label, non-comparative, randomized, multicenter phase II trial
- Conditions
- Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract, Adenocarinoma Locally Advanced
- Trial name
- NIFE (NCT03044587)
- Testing
- Arm NaI-IRI + 5-FU + Leucovorin (Arm A), Arm Cisplatin + Gemcitabine (Arm B)
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- AIO-Studien-gGmbH
Small Bowel Cancer, Colorectal Cancer
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer
- Trial name
- LIVELONG (NCT06101277)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, Davis
Biliary Tract Cancer, Gallbladder Cancer
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma
- Trial name
- VANGOGH (NCT00753675)
- Testing
- ZD6474, Vandetanib, Gemcitabine
- Where
- 15 sites in Italy
- Volunteers
- 174 people
- Sponsor
- Genzyme, a Sanofi Company
Cholangiocarcinoma
A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma
This is a prospective, observational and exploratory clinical study. The object of this study is to evaluate the accuracy of a novel serological risk model on blood samples in early diagnosis of cholangiocarcinoma patients.
- Trial name
- NCT06658587
- Testing
- No interventions
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Intrahepatic Cholangiocarcinoma
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
The study trial is a open-label, single-arm, multicenter phase II trial investigating the combined treatment of atezolizumab and derazantinib in patients with advanced intrahepatic cholangiocarcinoma with FGFR2…
- Trial name
- NCT05174650
- Testing
- Atezolizumab, Derazantinib
- Where
- 17 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis.
- Conditions
- Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage, Digestive System Neoplasm, Esophageal Carcinoma by AJCC V8 Stage
- Trial name
- NCT04929015
- Testing
- Biospecimen Collection - blood and tissue sample collection, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Intrahepatic Cholangiocarcinoma
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.
- Trial name
- NCT03521219
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Intrahepatic Cholangiocarcinoma
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.
- Trial name
- NCT06208462
- Testing
- Adebrelimab, Lenvatinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Intrahepatic Cholangiocellular Carcinoma
Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)
This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus Tislelizumab compared with FOLFOX in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line…
- Trial name
- NCT06860477
- Testing
- Tislelizumab, Lenvatinib, cryoablation
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Fudan University
Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well selumetinib works in treating patients with biliary cancer that cannot be removed by surgery.
- Conditions
- Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer, Unresectable Extrahepatic Bile Duct Cancer
- Trial name
- NCT00553332
- Testing
- selumetinib, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer
Patients With Primary Biliary Cholangitis
Primary biliary cholangitis (PBC) is a chronic autoimmune disease characterized by progressive destruction of the small intrahepatic bile ducts, leading to cholestasis and potential progression to cirrhosis.
- Conditions
- Primary Biliary Cholangitis, Intrahepatic Bile Duct Cancer, Cancer Liver
- Trial name
- BILIFLEX (NCT07573514)
- Testing
- Reflex AMA and ANA testing
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Intrahepatic Cholangiocarcinoma
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. Currently, one phase I dose escalation safety study has been completed in China and the United States respectively, both demonstrating excellent…
- Trial name
- NCT07522476
- Testing
- VG2025
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Virogin Biotech Ltd.